Rein Therapeutics, Inc. (RNTX)
0.58
-0.03
(-5.23%)
USD |
NASDAQ |
Nov 06, 10:20
Rein Therapeutics Enterprise Value : 56.85M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 56.85M |
| November 04, 2026 | 60.85M |
| November 03, 2026 | 61.61M |
| November 02, 2026 | 58.85M |
| October 30, 2026 | 61.82M |
| October 29, 2026 | 66.68M |
| October 28, 2026 | 65.66M |
| October 27, 2026 | 64.76M |
| October 26, 2026 | 54.38M |
| October 23, 2026 | 54.28M |
| October 22, 2026 | 56.02M |
| October 21, 2026 | 57.95M |
| October 20, 2026 | 55.40M |
| October 19, 2026 | 51.70M |
| October 16, 2026 | 54.99M |
| October 15, 2026 | 58.22M |
| October 14, 2026 | 54.62M |
| October 13, 2026 | 69.08M |
| October 12, 2026 | 71.68M |
| October 09, 2026 | 72.46M |
| October 08, 2026 | 70.34M |
| October 07, 2026 | 72.00M |
| October 06, 2026 | 75.12M |
| October 05, 2026 | 75.12M |
| October 02, 2026 | 73.03M |
| Date | Value |
|---|---|
| October 01, 2026 | 77.44M |
| September 30, 2026 | 73.31M |
| September 29, 2026 | 72.11M |
| September 28, 2026 | 66.20M |
| September 25, 2026 | 68.55M |
| September 24, 2026 | 68.17M |
| September 23, 2026 | 70.42M |
| September 22, 2026 | 72.52M |
| September 21, 2026 | 72.50M |
| September 18, 2026 | 72.97M |
| September 17, 2026 | 72.05M |
| September 16, 2026 | 64.58M |
| September 15, 2026 | 65.04M |
| September 14, 2026 | 72.20M |
| September 11, 2026 | 71.69M |
| September 10, 2026 | 71.33M |
| September 09, 2026 | 75.33M |
| September 08, 2026 | 78.33M |
| September 04, 2026 | 80.61M |
| September 03, 2026 | 76.71M |
| September 02, 2026 | 70.81M |
| September 01, 2026 | 68.91M |
| August 31, 2026 | 68.67M |
| August 28, 2026 | 69.72M |
| August 27, 2026 | 71.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.375M |
| Total Expenses (Quarterly) | 6.375M |
| EPS Diluted (Quarterly) | -0.095 |
| Earnings Yield | -296.2% |
| Normalized Earnings Yield | -164.16 |